Tonix Pharmaceuticals Announces Collaboration with Boston Children’s Hospital to Study Tnx-1500 (FC-Modified Anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in Animals

Tonix Pharmaceuticals Holding Corp. announced that it had entered into a sponsored research agreement with Boston Children’s Hospital to study TNX-15001 (Fc-modified anti-CD40L mAb) for the prevention of graft-versus-host diseases after hematopoietic stem cell transplantation in animals.